Journal of Molecular Endocrinology

References

1. ↵
   1. Adams DO

   1989 Molecular interactions in macrophage activation. Immunology Today 10 33–35.
2. ↵
   1. Agarwal AK,
   2. Rogerson FM,
   3. Mune T &
   4. White PC

   1995 Gene structure and chromosomal localization of the human HSD11K gene encoding the kidney (type 2) isozyme of 11 beta-hydroxysteroid dehydrogenase. Genomics 29 195–199.
3. ↵
   1. Albiston AL,
   2. Obeyesekere VR,
   3. Smith RE &
   4. Krozowski ZS

   1994 Cloning and tissue distribution of the human 11 beta-hydroxysteroid dehydrogenase type 2 enzyme. Molecular and Cellular Endocrinology 105 R11–R17.
4. ↵
   1. Alzamora R,
   2. Michea L &
   3. Marusic ET

   2000 Role of 11β-hydroxysteroid dehydrogenase in nongenomic aldosterone effects in human arteries. Hypertension 35 1099–1104.
5. ↵
   1. Armanini D,
   2. Strasser T &
   3. Weber PC

   1985a Characterization of aldosterone binding sites in circulating human mononuclear leukocytes. American Journal of Physiology 248 E388–E390.
6. ↵
   1. Armanini D,
   2. Witzgall H,
   3. Strasser T &
   4. Weber PC

   Mineralocorticoid and glucocorticoid receptors in circulating mononuclear leukocytes of patients with primary hyperaldosteronism. Cardiology 72 (Supplement 1) 1985b 99–101.
7. ↵
   1. Arriza JL,
   2. Weinberger C,
   3. Cerelli G,
   4. Glaser TM,
   5. Handelin BL,
   6. Housman DE &
   7. Evans RM

   1987 Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 237 268–275.
8. ↵
   1. Aubin JE

   1999 Osteoprogenitor cell frequency in rat bone marrow stromal populations: role for heterotypic cell–cell interactions in osteoblast differentiation. Journal of Cellular Biochemistry 72 396–410.
9. ↵
   1. Babior BM,
   2. Kipnes RS &
   3. Curnutte JT

   1973 Biological defense mechanisms. The production by leukocytes of superoxide, a potential bactericidal agent. Journal of Clinical Investigation 52 741–744.
10. ↵
    1. Bailey JM

    1991 New mechanisms for effects of anti-inflammatory glucocorticoids. Biofactors 3 97–102.
11. ↵
    1. Barish GD,
    2. Downes M,
    3. Alaynick WA,
    4. Yu RT,
    5. Ocampo CB,
    6. Bookout AL,
    7. Mangelsdorf DJ &
    8. Evans RM

    2005 A nuclear receptor atlas: macrophage activation. Molecular Endocrinology 19 2466–2477.
12. ↵
    1. Blasi ER,
    2. Rocha R,
    3. Rudolph AE,
    4. Blomme EA,
    5. Polly ML &
    6. McMahon EG

    2003 Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney International 63 1791–1800.
13. ↵
    1. Boldrick JC,
    2. Alizadeh AA,
    3. Diehn M,
    4. Dudoit S,
    5. Liu CL,
    6. Belcher CE,
    7. Botstein D,
    8. Staudt LM,
    9. Brown PO &
    10. Relman DA

    2002 Stereotyped and specific gene expression programs in human innate immune responses to bacteria. PNAS 99 972–977.
14. ↵
    1. Boyle WJ,
    2. Simonet WS &
    3. Lacey DL

    2003 Osteoclast differentiation and activation. Nature 423 337–342.
15. ↵
    1. Calo LA,
    2. Zaghetto F,
    3. Pagnin E,
    4. Davis PA,
    5. De Mozzi P,
    6. Sartorato P,
    7. Martire G,
    8. Fiore C &
    9. Armanini D

    2004 Effect of aldosterone and glycyrrhetinic acid on the protein expression of PAI-1 and p22(phox) in human mononuclear leukocytes. Journal of Clinical Endocrinology and Metabolism 89 1973–1976.
16. ↵
    1. Caprio M,
    2. Newfell BG,
    3. la Sala A,
    4. Baur W,
    5. Fabbri A,
    6. Rosano G,
    7. Mendelsohn ME &
    8. Jaffe IZ

    2008 Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion. Circulation Research 102 1359–1367.
17. ↵
    1. Chapman KE,
    2. Gilmour JS,
    3. Coutinho AE,
    4. Savill JS &
    5. Seckl JR

    2006 11Beta-hydroxysteroid dehydrogenase type 1 – a role in inflammation? Molecular and Cellular Endocrinology 248 3–8.
18. ↵
    1. Clark AR

    2007 Anti-inflammatory functions of glucocorticoid-induced genes. Molecular and Cellular Endocrinology 275 79–97.
19. ↵
    1. Connell JM,
    2. MacKenzie SM,
    3. Freel EM,
    4. Fraser R &
    5. Davies E

    2008 A lifetime of aldosterone excess: long-term consequences of altered regulation of aldosterone production for cardiovascular function. Endocrine Reviews 29 133–154.
20. ↵
    1. Coussens LM &
    2. Werb Z

    2002 Inflammation and cancer. Nature 420 860–867.
21. ↵
    1. Dalton DK,
    2. Pitts-Meek S,
    3. Keshav S,
    4. Figari IS,
    5. Bradley A &
    6. Stewart TA

    1993 Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. Science 259 1739–1742.
22. ↵
    1. Dandona P,
    2. Aljada A &
    3. Bandyopadhyay A

    2004 Inflammation: the link between insulin resistance, obesity and diabetes. Trends in Immunology 25 4–7.
23. ↵
    1. Davis JO

    1960 Mechanisms of salt and water retention in congestive heart failure. The importance of aldosterone. American Journal of Medicine 29 486–507.
24. ↵
    1. Desvergne B

    2008 PPARδ/β: the lobbyist switching macrophage allegiance in favor of metabolism. Cell Metabolism 7 467–469.
25. ↵
    1. Dewald O,
    2. Zymek P,
    3. Winkelmann K,
    4. Koerting A,
    5. Ren G,
    6. Abou-Khamis T,
    7. Michael LH,
    8. Rollins BJ,
    9. Entman ML &
    10. Frangogiannis NG

    2005 CCL2/monocyte chemoattractant protein-1 regulates inflammatory responses critical to healing myocardial infarcts. Circulation Research 96 881–889.
26. ↵
    1. Duffield JS,
    2. Forbes SJ,
    3. Constandinou CM,
    4. Clay S,
    5. Partolina M,
    6. Vuthoori S,
    7. Wu S,
    8. Lang R &
    9. Iredale JP

    2005 Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. Journal of Clinical Investigation 115 56–65.
27. ↵
    1. Edwards CR,
    2. Stewart PM,
    3. Burt D,
    4. Brett L,
    5. McIntyre MA,
    6. Sutanto WS,
    7. de Kloet ER &
    8. Monder C

    1988 Localisation of 11 β-hydroxysteroid dehydrogenase – tissue specific protector of the mineralocorticoid receptor. Lancet 2 986–989.
28. ↵
    1. Ehrchen J,
    2. Steinmuller L,
    3. Barczyk K,
    4. Tenbrock K,
    5. Nacken W,
    6. Eisenacher M,
    7. Nordhues U,
    8. Sorg C,
    9. Sunderkotter C &
    10. Roth J

    2007 Glucocorticoids induce differentiation of a specifically activated, anti-inflammatory subtype of human monocytes. Blood 109 1265–1274.
29. ↵
    1. Fraccarollo D,
    2. Galuppo P,
    3. Schraut S,
    4. Kneitz S,
    5. van Rooijen N,
    6. Ertl G &
    7. Bauersachs J

    2008 Immediate mineralocorticoid receptor blockade improves myocardial infarct healing by modulation of the inflammatory response. Hypertension 51 905–914.
30. ↵
    1. Fujisawa G,
    2. Dilley R,
    3. Fullerton MJ &
    4. Funder JW

    2001 Experimental cardiac fibrosis: differential time course of responses to mineralocorticoid-salt administration. Endocrinology 142 3625–3631.
31. ↵
    1. Funder JW,
    2. Pearce PT,
    3. Smith R &
    4. Smith AI

    1988 Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 242 583–585.
32. ↵
    1. Funder JW,
    2. Pearce PT,
    3. Smith R &
    4. Campbell J

    1989 Vascular type I aldosterone binding sites are physiological mineralocorticoid receptors. Endocrinology 125 2224–2226.
33. ↵
    1. Gehrmann J,
    2. Matsumoto Y &
    3. Kreutzberg GW

    1995 Microglia: intrinsic immuneffector cell of the brain. Brain Research. Brain Research Reviews 20 269–287.
34. ↵
    1. Gilmour JS,
    2. Coutinho AE,
    3. Cailhier JF,
    4. Man TY,
    5. Clay M,
    6. Thomas G,
    7. Harris HJ,
    8. Mullins JJ,
    9. Seckl JR,
    10. Savill JS
    11. et al.

    2006 Local amplification of glucocorticoids by 11 beta-hydroxysteroid dehydrogenase type 1 promotes macrophage phagocytosis of apoptotic leukocytes. Journal of Immunology 176 7605–7611.
35. ↵
    1. Goerdt S &
    2. Orfanos CE

    1999 Other functions, other genes: alternative activation of antigen-presenting cells. Immunity 10 137–142.
36. ↵
    1. Goerdt S,
    2. Politz O,
    3. Schledzewski K,
    4. Birk R,
    5. Gratchev A,
    6. Guillot P,
    7. Hakiy N,
    8. Klemke CD,
    9. Dippel E,
    10. Kodelja V
    11. et al.

    1999 Alternative versus classical activation of macrophages. Pathobiology 67 222–226.
37. ↵
    1. Gordon S

    1995 The macrophage. BioEssays 17 977–986.
38. ↵
    1. Gordon S

    2003 Alternative activation of macrophages. Nature Reviews. Immunology 3 23–35.
39. ↵
    1. Grunfeld JP

    1990 Glucocorticoids in blood pressure regulation. Hormone Research 34 111–113.
40. ↵
    1. Harkonen PL &
    2. Vaananen HK

    2006 Monocyte-macrophage system as a target for estrogen and selective estrogen receptor modulators. Annals of the New York Academy of Sciences 1089 218–227.
41. ↵
    1. Hench PS,
    2. Slocumb CH,
    3. Polley HF &
    4. Kendal EC

    1950 Effect of cortisone and pituitary adrenocorticotropic hormone (ACTH) on rheumatic diseases. Journal of the American Medical Association 144 1327–1335.
42. ↵
    1. Hotamisligil GS

    2006 Inflammation and metabolic disorders. Nature 444 860–867.
43. ↵
    1. Hume DA,
    2. Ross IL,
    3. Himes SR,
    4. Sasmono RT,
    5. Wells CA &
    6. Ravasi T

    2002 The mononuclear phagocyte system revisited. Journal of Leukocyte Biology 72 621–627.
44. ↵
    1. Ishii T,
    2. Masuzaki H,
    3. Tanaka T,
    4. Arai N,
    5. Yasue S,
    6. Kobayashi N,
    7. Tomita T,
    8. Noguchi M,
    9. Fujikura J,
    10. Ebihara K
    11. et al.

    2007 Augmentation of 11β-hydroxysteroid dehydrogenase type 1 in LPS-activated J774.1 macrophages – role of 11β-HSD1 in pro-inflammatory properties in macrophages. FEBS Letters 581 349–354.
45. ↵
    1. Kaden JJ,
    2. Bickelhaupt S,
    3. Grobholz R,
    4. Haase KK,
    5. Sarikoc A,
    6. Kilic R,
    7. Brueckmann M,
    8. Lang S,
    9. Zahn I,
    10. Vahl C
    11. et al.

    2004 Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulate aortic valve calcification. Journal of Molecular and Cellular Cardiology 36 57–66.
46. ↵
    1. Keidar S,
    2. Kaplan M,
    3. Pavlotzky E,
    4. Coleman R,
    5. Hayek T,
    6. Hamoud S &
    7. Aviram M

    2004 Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone. Circulation 109 2213–2220.
47. ↵
    1. Kim HJ,
    2. Zhao H,
    3. Kitaura H,
    4. Bhattacharyya S,
    5. Brewer JA,
    6. Muglia LJ,
    7. Ross FP &
    8. Teitelbaum SL

    2006 Glucocorticoids suppress bone formation via the osteoclast. Journal of Clinical Investigation 116 2152–2160.
48. ↵
    1. Kim HJ,
    2. Zhao H,
    3. Kitaura H,
    4. Bhattacharyya S,
    5. Brewer JA,
    6. Muglia LJ,
    7. Patrick Ross F &
    8. Teitelbaum SL

    2007 Glucocorticoids and the osteoclast. Annals of the New York Academy of Sciences 1116 335–339.
49. ↵
    1. Kirkham P

    2007 Oxidative stress and macrophage function: a failure to resolve the inflammatory response. Biochemical Society Transactions 35 284–287.
50. ↵
    1. Krozowski ZS &
    2. Funder JW

    1983 Renal mineralocorticoid receptors and hippocampal corticosterone-binding species have identical intrinsic steroid specificity. PNAS 80 6056–6060.
51. ↵
    1. Kuhlmann D,
    2. Ragan C,
    3. Ferrebee JW,
    4. Atchley DW &
    5. Loeb RF

    1939 Toxic effects of desoxycorticosterone esters in dogs. Science 90 496–497.
52. ↵
    1. Lakshmi V &
    2. Monder C

    1988 Purification and characterization of the corticosteroid 11 β-dehydrogenase component of the rat liver 11 beta-hydroxysteroid dehydrogenase complex. Endocrinology 123 2390–2398.
53. ↵
    1. Libby P

    2002 Inflammation in atherosclerosis. Nature 420 868–874.
54. ↵
    1. Lim HY,
    2. Muller N,
    3. Herold MJ,
    4. van den Brandt J &
    5. Reichardt HM

    2007 Glucocorticoids exert opposing effects on macrophage function dependent on their concentration. Immunology 122 47–53.
55. ↵
    1. Ling EA &
    2. Wong WC

    1993 The origin and nature of ramified and amoeboid microglia: a historical review and current concepts. Glia 7 9–18.
56. ↵
    1. Liu Y,
    2. Cousin JM,
    3. Hughes J,
    4. Van Damme J,
    5. Seckl JR,
    6. Haslett C,
    7. Dransfield I,
    8. Savill J &
    9. Rossi AG

    1999 Glucocorticoids promote nonphlogistic phagocytosis of apoptotic leukocytes. Journal of Immunology 162 3639–3646.
57. ↵
    1. Lombes M,
    2. Oblin ME,
    3. Gasc JM,
    4. Baulieu EE,
    5. Farman N &
    6. Bonvalet JP

    1992 Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor. Circulation Research 71 503–510.
58. ↵
    1. Lowy MT

    1989 Quantification of type I and II adrenal steroid receptors in neuronal, lymphoid and pituitary tissues. Brain Research 503 191–197.
59. ↵
    1. Lupher ML Jr. &
    2. Gallatin WM

    2006 Regulation of fibrosis by the immune system. Advances in Immunology 89 245–288.
60. ↵
    1. Mantovani A,
    2. Sica A,
    3. Sozzani S,
    4. Allavena P,
    5. Vecchi A &
    6. Locati M

    2004 The chemokine system in diverse forms of macrophage activation and polarization. Trends in Immunology 25 677–686.
61. ↵
    1. Mantovani A,
    2. Sica A &
    3. Locati M

    2007 New vistas on macrophage differentiation and activation. European Journal of Immunology 37 14–16.
62. ↵
    1. Martinez FO,
    2. Sica A,
    3. Mantovani A &
    4. Locati M

    2008 Macrophage activation and polarization. Frontiers in Bioscience 13 453–461.
63. ↵
    1. Masuzaki H,
    2. Paterson J,
    3. Shinyama H,
    4. Morton NM,
    5. Mullins JJ,
    6. Seckl JR &
    7. Flier JS

    2001 A transgenic model of visceral obesity and the metabolic syndrome. Science 294 2166–2170.
64. ↵
    1. Masuzaki H,
    2. Yamamoto H,
    3. Kenyon CJ,
    4. Elmquist JK,
    5. Morton NM,
    6. Paterson JM,
    7. Shinyama H,
    8. Sharp MG,
    9. Fleming S,
    10. Mullins JJ
    11. et al.

    2003 Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. Journal of Clinical Investigation 112 83–90.
65. ↵
    1. McEwen BS &
    2. Wallach G

    1973 Corticosterone binding to hippocampus: nuclear and cytosol binding in vitro. Brain Research 57 373–386.
66. ↵
    1. McKenna NJ &
    2. O'Malley BW

    2002 Combinatorial control of gene expression by nuclear receptors and coregulators. Cell 108 465–474.
67. ↵
    1. Miller AH,
    2. Spencer RL,
    3. Stein M &
    4. McEwen BS

    1990 Adrenal steroid receptor binding in spleen and thymus after stress or dexamethasone. American Journal of Physiology 259 E405–E412.
68. ↵
    1. Miller AH,
    2. Spencer RL,
    3. Husain A,
    4. Rhee R,
    5. McEwen BS &
    6. Stein M

    1993 Differential expression of type I adrenal steroid receptors in immune tissues is associated with tissue-specific regulation of type II receptors by aldosterone. Endocrinology 133 2133–2140.
69. ↵
    1. Miller AH,
    2. Spencer RL,
    3. Hassett J,
    4. Kim C,
    5. Rhee R,
    6. Ciurea D,
    7. Dhabhar F,
    8. McEwen B &
    9. Stein M

    1994 Effects of selective type I and II adrenal steroid agonists on immune cell distribution. Endocrinology 135 1934–1944.
70. ↵
    1. Monder C

    1993 The forms and functions of 11 β-hydroxysteroid dehydrogenase. Journal of Steroid Biochemistry and Molecular Biology 45 161–165.
71. ↵
    1. Mosser DM

    2003 The many faces of macrophage activation. Journal of Leukocyte Biology 73 209–212.
72. ↵
    1. Nau GJ,
    2. Richmond JF,
    3. Schlesinger A,
    4. Jennings EG,
    5. Lander ES &
    6. Young RA

    2002 Human macrophage activation programs induced by bacterial pathogens. PNAS 99 1503–1508.
73. ↵
    1. Neves MF,
    2. Amiri F,
    3. Virdis A,
    4. Diep QN &
    5. Schiffrin EL

    2005 Role of aldosterone in angiotensin II-induced cardiac and aortic inflammation, fibrosis, and hypertrophy. Canadian Journal of Physiology and Pharmacology 83 999–1006.
74. ↵
    1. Nishimura H,
    2. Ito Y,
    3. Mizuno M,
    4. Tanaka A,
    5. Morita Y,
    6. Maruyama S,
    7. Yuzawa Y &
    8. Matsuo S

    2008 Mineralocorticoid receptor blockade ameliorates peritoneal fibrosis in new rat peritonitis model. American Journal of Physiology. Renal Physiology 294 F1084–F1093.
75. ↵
    1. Norman RA Jr.,
    2. Dzielak DJ,
    3. Bost KL,
    4. Khraibi AA &
    5. Galloway PG

    1985 Immune system dysfunction contributes to the aetiology of spontaneous hypertension. Journal of Hypertension 3 261–268.
76. ↵
    1. Ong SL,
    2. Zhang Y &
    3. Whitworth JA

    2008 Reactive oxygen species and glucocorticoid-induced hypertension. Clinical and Experimental Pharmacology and Physiology 35 477–482.
77. ↵
    1. Pearce PT &
    2. Funder JW

    1988 Steroid binding to cardiac type I receptors: in vivo studies. Journal of Hypertension 6 S131–S133.
78. ↵
    1. Persy VP,
    2. Verhulst A,
    3. Ysebaert DK,
    4. De Greef KE &
    5. De Broe ME

    2003 Reduced postischemic macrophage infiltration and interstitial fibrosis in osteopontin knockout mice. Kidney International 63 543–553.
79. ↵
    1. Poon M,
    2. Gertz SD,
    3. Fallon JT,
    4. Wiegman P,
    5. Berman JW,
    6. Sarembock IJ &
    7. Taubman MB

    2001 Dexamethasone inhibits macrophage accumulation after balloon arterial injury in cholesterol fed rabbits. Atherosclerosis 155 371–380.
80. ↵
    1. Preusch MR,
    2. Rattazzi M,
    3. Albrecht C,
    4. Merle U,
    5. Tuckermann J,
    6. Schutz G,
    7. Blessing E,
    8. Zoppellaro G,
    9. Pauletto P,
    10. Krempien R
    11. et al.

    2008 Critical role of macrophages in glucocorticoid driven vascular calcification in a mouse-model of atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology 28 2158–2164.
81. ↵
    1. Purpura KA,
    2. Aubin JE &
    3. Zandstra PW

    2004 Sustained in vitro expansion of bone progenitors is cell density dependent. Stem Cells 22 39–50.
82. ↵
    1. Rickard AJ,
    2. Funder JW,
    3. Morgan J,
    4. Fuller PJ &
    5. Young MJ

    2007 Does glucocorticoid receptor blockade exacerbate tissue damage after mineralocorticoid/salt administration? Endocrinology 148 4829–4835.
83. ↵
    1. Rocha R,
    2. Stier CT Jr.,
    3. Kifor I,
    4. Ochoa-Maya MR,
    5. Rennke HG,
    6. Williams GH &
    7. Adler GK

    2000 Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 141 3871–3878.
84. ↵
    1. Rocha R,
    2. Rudolph AE,
    3. Frierdich GE,
    4. Nachowiak DA,
    5. Kekec BK,
    6. Blomme EA,
    7. McMahon EG &
    8. Delyani JA

    2002 Aldosterone induces a vascular inflammatory phenotype in the rat heart. American Journal of Physiology. Heart and Circulatory Physiology 283 H1802–H1810.
85. ↵
    1. Rodriguez-Iturbe B,
    2. Pons H,
    3. Quiroz Y,
    4. Gordon K,
    5. Rincon J,
    6. Chavez M,
    7. Parra G,
    8. Herrera-Acosta J,
    9. Gomez-Garre D,
    10. Largo R
    11. et al.

    2001 Mycophenolate mofetil prevents salt-sensitive hypertension resulting from angiotensin II exposure. Kidney International 59 2222–2232.
86. ↵
    1. Rousseau G,
    2. Baxter JD,
    3. Funder JW,
    4. Edelman IS &
    5. Tomkins GM

    1972 Glucocorticoid and mineralocorticoid receptors for aldosterone. Journal of Steroid Biochemistry 3 219–227.
87. ↵
    1. Seckl JR,
    2. Morton NM,
    3. Chapman KE &
    4. Walker BR

    2004 Glucocorticoids and 11β-hydroxysteroid dehydrogenase in adipose tissue. Recent Progress in Hormone Research 59 359–393.
88. ↵
    1. Sheppard KE &
    2. Funder JW

    1987 Equivalent affinity of aldosterone and corticosterone for type I receptors in kidney and hippocampus: direct binding studies. Journal of Steroid Biochemistry 28 737–742.
89. ↵
    1. Shoelson SE,
    2. Lee J &
    3. Goldfine AB

    2006 Inflammation and insulin resistance. Journal of Clinical Investigation 116 1793–1801.
90. ↵
    1. Smith E,
    2. Redman RA,
    3. Logg CR,
    4. Coetzee GA,
    5. Kasahara N &
    6. Frenkel B

    2000 Glucocorticoids inhibit developmental stage-specific osteoblast cell cycle. Dissociation of cyclin A-cyclin-dependent kinase 2 from E2F4-p130 complexes. Journal of Biological Chemistry 275 19992–20001.
91. ↵
    1. Stein M,
    2. Keshav S,
    3. Harris N &
    4. Gordon S

    1992 Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. Journal of Experimental Medicine 176 287–292.
92. ↵
    1. Streit WJ,
    2. Graeber MB &
    3. Kreutzberg GW

    1988 Functional plasticity of microglia: a review. Glia 1 301–307.
93. ↵
    1. Suzuki H,
    2. Schmid-Schonbein GW,
    3. Suematsu M,
    4. DeLano FA,
    5. Forrest MJ,
    6. Miyasaka M &
    7. Zweifach BW

    1994 Impaired leukocyte–endothelial cell interaction in spontaneously hypertensive rats. Hypertension 24 719–727.
94. ↵
    1. Suzuki H,
    2. Zweifach BW,
    3. Forrest MJ &
    4. Schmid-Schonbein GW

    1995 Modification of leukocyte adhesion in spontaneously hypertensive rats by adrenal corticosteroids. Journal of Leukocyte Biology 57 20–26.
95. ↵
    1. Suzuki J,
    2. Iwai M,
    3. Mogi M,
    4. Oshita A,
    5. Yoshii T,
    6. Higaki J &
    7. Horiuchi M

    2006 Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation. Arteriosclerosis, Thrombosis, and Vascular Biology 26 917–921.
96. ↵
    1. Szekanecz Z &
    2. Koch AE

    2007 Macrophages and their products in rheumatoid arthritis. Current Opinions in Rheumatology 19 289–295.
97. ↵
    1. Tagami M &
    2. Yamori Y

    1988 Morphological analysis of the pathogenesis of hypertensive cerebrovascular lesions: role of monocytes and platelets in intracerebral vessel occlusions. Japanese Circulation Journal 52 1351–1356.
98. ↵
    1. Takeda Y,
    2. Miyamori I,
    3. Yoneda T,
    4. Iki K,
    5. Hatakeyama H,
    6. Blair IA,
    7. Hsieh FY &
    8. Takeda R

    1995 Production of aldosterone in isolated rat blood vessels. Hypertension 25 170–173.
99. ↵
    1. Tanaka J,
    2. Fujita H,
    3. Matsuda S,
    4. Toku K,
    5. Sakanaka M &
    6. Maeda N

    1997 Glucocorticoid- and mineralocorticoid receptors in microglial cells: the two receptors mediate differential effects of corticosteroids. Glia 20 23–37.
100. ↵
     1. Teitelbaum SL &
     2. Ross FP

     2003 Genetic regulation of osteoclast development and function. Nature Reviews. Genetics 4 638–649.
101. ↵
     1. Thieringer R,
     2. Le Grand CB,
     3. Carbin L,
     4. Cai TQ,
     5. Wong B,
     6. Wright SD &
     7. Hermanowski-Vosatka A

     2001 11Beta-hydroxysteroid dehydrogenase type 1 is induced in human monocytes upon differentiation to macrophages. Journal of Immunology 167 30–35.
102. ↵
     1. Tuckermann JP,
     2. Kleiman A,
     3. McPherson KG &
     4. Reichardt HM

     2005 Molecular mechanisms of glucocorticoids in the control of inflammation and lymphocyte apoptosis. Critical Reviews in Clinical Laboratory Sciences 42 71–104.
103. ↵
     1. Villa AE,
     2. Guzman LA,
     3. Chen W,
     4. Golomb G,
     5. Levy RJ &
     6. Topol EJ

     1994 Local delivery of dexamethasone for prevention of neointimal proliferation in a rat model of balloon angioplasty. Journal of Clinical Investigation 93 1243–1249.
104. ↵
     1. Volkman A &
     2. Gowans JL

     1965 The origin of macrophages from bone marrow in the rat. British Journal of Experimental Pathology 46 62–70.
105. ↵
     1. Waki H,
     2. Liu B,
     3. Miyake M,
     4. Katahira K,
     5. Murphy D,
     6. Kasparov S &
     7. Paton JF

     2007 Junctional adhesion molecule-1 is upregulated in spontaneously hypertensive rats: evidence for a prohypertensive role within the brain stem. Hypertension 49 1321–1327.
106. ↵
     1. Waki H,
     2. Gouraud SS,
     3. Maeda M &
     4. Paton JF

     2008 Gene expression profiles of major cytokines in the nucleus tractus solitarii of the spontaneously hypertensive rat. Autonomic Neuroscience 142 40–44.
107. ↵
     1. Walker BR

     2007 Glucocorticoids and cardiovascular disease. European Journal of Endocrinology 157 545–559.
108. ↵
     1. Weinstein RS

     2001 Glucocorticoid-induced osteoporosis. Reviews in Endocrine and Metabolic Disorders 2 65–73.
109. ↵
     1. Weinstein RS,
     2. Jilka RL,
     3. Parfitt AM &
     4. Manolagas SC

     1998 Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. Journal of Clinical Investigation 102 274–282.
110. ↵
     1. Weisberg SP,
     2. McCann D,
     3. Desai M,
     4. Rosenbaum M,
     5. Leibel RL &
     6. Ferrante AW Jr.

     2003 Obesity is associated with macrophage accumulation in adipose tissue. Journal of Clinical Investigation 112 1796–1808.
111. ↵
     1. Whitworth JA

     1994 Studies on the mechanisms of glucocorticoid hypertension in humans. Blood Pressure 3 24–32.
112. ↵
     1. Whitworth JA,
     2. Mangos GJ &
     3. Kelly JJ

     2000 Cushing, cortisol, and cardiovascular disease. Hypertension 36 912–916.
113. ↵
     1. Whitworth JA,
     2. Schyvens CG,
     3. Zhang Y,
     4. Andrews MC,
     5. Mangos GJ &
     6. Kelly JJ

     2002 The nitric oxide system in glucocorticoid-induced hypertension. Journal of Hypertension 20 1035–1043.
114. ↵
     1. Wynn TA

     2008 Cellular and molecular mechanisms of fibrosis. Journal of Pathology 214 199–210.
115. ↵
     1. Xu H,
     2. Barnes GT,
     3. Yang Q,
     4. Tan G,
     5. Yang D,
     6. Chou CJ,
     7. Sole J,
     8. Nichols A,
     9. Ross JS,
     10. Tartaglia LA
     11. et al.

     2003 Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. Journal of Clinical Investigation 112 1821–1830.
116. ↵
     1. Yan ZQ &
     2. Hansson GK

     2007 Innate immunity, macrophage activation, and atherosclerosis. Immunological Reviews 219 187–203.
117. ↵
     1. Young MJ

     2008 Mechanisms of mineralocorticoid receptor-mediated cardiac fibrosis and vascular inflammation. Current Opinion in Nephrology and Hypertension 17 174–180.
118. ↵
     1. Young MJ,
     2. Moussa L,
     3. Dilley R &
     4. Funder JW

     2003 Early inflammatory responses in experimental cardiac hypertrophy and fibrosis: effects of 11 beta-hydroxysteroid dehydrogenase inactivation. Endocrinology 144 1121–1125.
119. ↵
     1. Zeyda M &
     2. Stulnig TM

     2007 Adipose tissue macrophages. Immunology Letters 112 61–67.
120. ↵
     1. Zhang X &
     2. Mosser DM

     2008 Macrophage activation by endogenous danger signals. Journal of Pathology 214 161–178.